94994-29-3

Upstream product

• 23760-80-7 4-phenylbicyclo<2.2.2>octane-1-methanol 
• 953-69-5 4-phenylbicyclo<2.2.2>octane-1-carboxylic acid 
• 942999-71-5 N-methoxy-N-methyl-1-phenylbicyclo[2.2.2]octane-4-carboxamide 
• 23062-51-3 methyl 4-bromo-bicyclo[2.2.2]octane-1-carboxylate 
• 23062-52-4 methyl 4-phenylbicyclo<2.2.2>octane-1-carboxylate 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 

Downstream Products

• 94993-94-9 1-(2,2-Difluoro-vinyl)-4-phenyl-bicyclo[2.2.2]octane 
• 942999-73-7 (Z)-4-[2-methoxyethenyl]-1-phenyl-bicyclo[2.2.2]octane 
• 942999-72-6 (E)-4-[2-methoxyethenyl]-1-phenyl-bicyclo[2.2.2]octane 

Relevant academic research and scientific papers

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists

Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffold

CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF

Disclosed are method of treating fibrotic conditions using carboranes and carborane analogs. Also disclosed herein are compounds comprising dicarba-closo-dodecaborane or a dicarba-closo-dodecaborane analog. The compounds can be, for example, estrogen rece

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Nickel-Catalyzed Selective Reduction of Carboxylic Acids to Aldehydes

The direct reduction of carboxylic acids to aldehydes is a fundamental transformation in organic synthesis. The combination of an air-stable Ni precatalyst, dimethyl dicarbonate as an activator, and silane reductant effects this reduction for a wide variety of substrates, including pharmaceutically relevant structures, in good yields and with no overreduction to alcohols. Moreover, this methodology is scalable, allows access to deuterated aldehydes, and is also compatible with one-pot utilization of the aldehyde products.

PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS

Formula (I). Compounds of formula (I) or salts thereof, wherein A1, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

Polar Substituent Effects on 19F Chemical Shifts of Aryl and Vinyl Fluorides: A Fluorine-19 Nuclear Magnetic Resonance Study of Some 1,1-Difluoro-2-(4-substituted-bicyclooct-1-yl)ethenes

An extensive series of 1,1-difluoro-2-(4-substituted-bicyclooct-1-yl)ethenes (2) covering a diverse range of substituents ( X = H, NO2, CN, CF3, COOCH3, F, Cl, Br, OCH3, C6H5, C2H, C2Si(CH3)3, CH3, and C(CH3)3) have been synthesized and their 19F N